SCHEMBL476650

SCHEMBL476650

Cc1cccc(C(F)(F)F)c1F

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MPL P40238 3/20 0.44
KIF11 P52732 1/20 0.44
HSD11B1 P28845 4/20 0.41
GABRA1 P14867 1/20 0.40
GABRB2 P47870 1/20 0.40
ACHE P22303 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
GPBAR1 Q8TDU6 1/20 0.38
NOTUM Q6P988 1/20 0.37
SCN8A Q9UQD0 1/20 0.37
P2RX7 Q99572 1/20 0.37
AR P10275 2/20 0.37
CTSS P25774 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2A6 P11509 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8343301 0.84 KIF11 (0.42) MPLKIF11HSD11B1GABRA1GABRB2
SCHEMBL9882817 0.84 GABRA1 (0.43) MPLKIF11HSD11B1GABRA1GABRB2
SCHEMBL8846936 0.82 KIF11 (0.41) MPLKIF11HSD11B1GABRA1GABRB2
SCHEMBL7601747 0.82 MPL (0.46) MPLKIF11HSD11B1IDO1TDO2
SCHEMBL9626868 0.81 GABRA1 (0.56) KIF11GABRA1GABRB2ACHECYP1A2
SCHEMBL25078710 0.79 KIF11 (0.40) MPLKIF11HSD11B1GABRA1GABRB2
SCHEMBL30867018 0.78 TRPA1 (0.48) HSD11B1GABRA1GABRB2ACHENOTUM
SCHEMBL3821590 0.78 TRPA1 (0.48) HSD11B1GABRA1GABRB2ACHENOTUM
SCHEMBL11698248 0.78 PDE2A (0.42) MPLKIF11HSD11B1NOTUMCTSS
SCHEMBL30018336 0.77 KIF11 (0.45) MPLKIF11GABRA1GABRB2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951225-B1 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-02-01 EP claimed
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2008-11-06 US claimed
EP-1951225-A2 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF sanofi-aventis (FR) 2008-08-06 EP claimed
WO-2007057571-A2 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-24 WO claimed
US-6495540-B2 HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR BRISTOL - MYERS SQUIBB PHARMA COMPANY 2002-12-17 US claimed
US-20020010172-A1 Lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-01-24 US claimed
US-20240360124-A1 Bromodomain Inhibitors ABBVIE INC. (US) 2024-10-31 US disclosed
EP-4400172-A2 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS Incyte Holdings Corporation (US) 2024-07-17 EP disclosed
EP-4289839-A1 NOVEL AURORA KINASE INHIBITOR AND USE THEREOF Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2023-12-13 EP disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
US-11814380-B2 Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-11-14 US disclosed
US-11814380-B2 Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-11-14 US disclosed
WO-2023180345-A1 TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2023-09-28 WO disclosed
US-20060094739-A1 3-Aryl-3-hydroxy-2-methylenepropionic acid esters as fungicides ATP CAPITAL LP 2006-05-04 US disclosed
WO-2006010965-A1 INDOLE-2 -CARBOXAMIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-02-02 WO disclosed
WO-2005115148-A1 3-ARYL-3-HYDROXY-2-METHYLENEPROPIONIC ACID ESTERS AS FUNGICIDES CROPSOLUTION, INC. (US) 2005-12-08 WO disclosed
EP-1267906-A1 LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2003-01-02 EP disclosed
US-6495540-B2 HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR BRISTOL - MYERS SQUIBB PHARMA COMPANY 2002-12-17 US disclosed
US-20020010172-A1 Lactams as inhibitors of A-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-01-24 US disclosed
WO-2001072324-A1 LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 MPL 510/4885KIF11 4867/4885HSD11B1 1183/4885
US-11814380-B2 Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors SOS1, SOST, BMP1 MPL 864/4885KIF11 4843/4885HSD11B1 2335/4885
US-20020010172-A1 Lactams as inhibitors of A-beta protein production BACE1, APP, APH1A MPL 4454/4885KIF11 4190/4885HSD11B1 759/4885
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF F12, ECI1, NQO2 MPL 1593/4885KIF11 2727/4885HSD11B1 552/4885
US-20060094739-A1 3-Aryl-3-hydroxy-2-methylenepropionic acid esters as fungicides CYP51A1, DDT, CYP21A2 MPL 4653/4885KIF11 3745/4885HSD11B1 104/4885
US-20240360124-A1 Bromodomain Inhibitors BRD4, BRD3, BRD1 MPL 3479/4885KIF11 2318/4885HSD11B1 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.